201 related articles for article (PubMed ID: 23720720)
41. Hepatitis C virus entry: role of host and viral factors.
Samreen B; Khaliq S; Ashfaq UA; Khan M; Afzal N; Shahzad MA; Riaz S; Jahan S
Infect Genet Evol; 2012 Dec; 12(8):1699-709. PubMed ID: 22878095
[TBL] [Abstract][Full Text] [Related]
42. The hepatitis C virus and its hepatic environment: a toxic but finely tuned partnership.
Perrault M; Pécheur EI
Biochem J; 2009 Oct; 423(3):303-14. PubMed ID: 19807698
[TBL] [Abstract][Full Text] [Related]
43. Building a mechanistic mathematical model of hepatitis C virus entry.
Kalemera M; Mincheva D; Grove J; Illingworth CJR
PLoS Comput Biol; 2019 Mar; 15(3):e1006905. PubMed ID: 30883541
[TBL] [Abstract][Full Text] [Related]
44. Occludin-Knockout Human Hepatic Huh7.5.1-8-Derived Cells Are Completely Resistant to Hepatitis C Virus Infection.
Shirasago Y; Shimizu Y; Tanida I; Suzuki T; Suzuki R; Sugiyama K; Wakita T; Hanada K; Yagi K; Kondoh M; Fukasawa M
Biol Pharm Bull; 2016 May; 39(5):839-48. PubMed ID: 26887345
[TBL] [Abstract][Full Text] [Related]
45. Hepatitis C Virus Infection of Human Thyrocytes: Metabolic, Hormonal, and Immunological Implications.
Hammerstad SS; Blackard JT; Lombardi A; Owen RP; Concepcion E; Yi Z; Zhang W; Tomer Y
J Clin Endocrinol Metab; 2020 Apr; 105(4):1157-68. PubMed ID: 31784757
[TBL] [Abstract][Full Text] [Related]
46. Hepatitis C virus receptors claudin-1 and occludin after liver transplantation and influence on early viral kinetics.
Mensa L; Crespo G; Gastinger MJ; Kabat J; Pérez-del-Pulgar S; Miquel R; Emerson SU; Purcell RH; Forns X
Hepatology; 2011 May; 53(5):1436-45. PubMed ID: 21294144
[TBL] [Abstract][Full Text] [Related]
47. Impact of single nucleotide polymorphisms in the essential HCV entry factor CD81 on HCV infectivity and neutralization.
Deest M; Westhaus S; Steinmann E; Manns MP; von Hahn T; Ciesek S
Antiviral Res; 2014 Jan; 101():37-44. PubMed ID: 24211330
[TBL] [Abstract][Full Text] [Related]
48. Hepatitis C virus entry: potential receptors and their biological functions.
Cocquerel L; Voisset C; Dubuisson J
J Gen Virol; 2006 May; 87(Pt 5):1075-1084. PubMed ID: 16603507
[TBL] [Abstract][Full Text] [Related]
49. Steps and Routes of HCV Infection: The Great Promise of New Anti-Viral Targets.
Crema A; Ponzetto A; Clementi M; Carloni G
Curr Drug Targets; 2015; 16(7):757-70. PubMed ID: 25694122
[TBL] [Abstract][Full Text] [Related]
50. Hepatitis C virus is restricted at both entry and replication in mouse hepatocytes.
Park IW; Ndjomou J; Fan Y; Henao-Mejia J; He JJ
Biochem Biophys Res Commun; 2009 Sep; 387(3):489-93. PubMed ID: 19619513
[TBL] [Abstract][Full Text] [Related]
51. Adaptation of hepatitis C virus to mouse CD81 permits infection of mouse cells in the absence of human entry factors.
Bitzegeio J; Bankwitz D; Hueging K; Haid S; Brohm C; Zeisel MB; Herrmann E; Iken M; Ott M; Baumert TF; Pietschmann T
PLoS Pathog; 2010 Jul; 6(7):e1000978. PubMed ID: 20617177
[TBL] [Abstract][Full Text] [Related]
52. Hepatitis C virus E2 links soluble human CD81 and SR-B1 protein.
Heo TH; Lee SM; Bartosch B; Cosset FL; Kang CY
Virus Res; 2006 Oct; 121(1):58-64. PubMed ID: 16725222
[TBL] [Abstract][Full Text] [Related]
53. Hepatitis C virus entry into hepatocytes: molecular mechanisms and targets for antiviral therapies.
Zeisel MB; Fofana I; Fafi-Kremer S; Baumert TF
J Hepatol; 2011 Mar; 54(3):566-76. PubMed ID: 21146244
[TBL] [Abstract][Full Text] [Related]
54. Primary hepatocytes of Tupaia belangeri as a potential model for hepatitis C virus infection.
Zhao X; Tang ZY; Klumpp B; Wolff-Vorbeck G; Barth H; Levy S; von Weizsäcker F; Blum HE; Baumert TF
J Clin Invest; 2002 Jan; 109(2):221-32. PubMed ID: 11805134
[TBL] [Abstract][Full Text] [Related]
55. Small molecule scavenger receptor BI antagonists are potent HCV entry inhibitors.
Syder AJ; Lee H; Zeisel MB; Grove J; Soulier E; Macdonald J; Chow S; Chang J; Baumert TF; McKeating JA; McKelvy J; Wong-Staal F
J Hepatol; 2011 Jan; 54(1):48-55. PubMed ID: 20932595
[TBL] [Abstract][Full Text] [Related]
56. Significance of palmitoylation of CD81 on its association with tetraspanin-enriched microdomains and mediating hepatitis C virus cell entry.
Zhu YZ; Luo Y; Cao MM; Liu Y; Liu XQ; Wang W; Wu DG; Guan M; Xu QQ; Ren H; Zhao P; Qi ZT
Virology; 2012 Aug; 429(2):112-23. PubMed ID: 22560863
[TBL] [Abstract][Full Text] [Related]
57. CD81 is required for hepatitis C virus glycoprotein-mediated viral infection.
Zhang J; Randall G; Higginbottom A; Monk P; Rice CM; McKeating JA
J Virol; 2004 Feb; 78(3):1448-55. PubMed ID: 14722300
[TBL] [Abstract][Full Text] [Related]
58. Apolipoprotein E on hepatitis C virion facilitates infection through interaction with low-density lipoprotein receptor.
Owen DM; Huang H; Ye J; Gale M
Virology; 2009 Nov; 394(1):99-108. PubMed ID: 19751943
[TBL] [Abstract][Full Text] [Related]
59. MiR-122 decreases HCV entry into hepatocytes through binding to the 3' UTR of OCLN mRNA.
Sendi H; Mehrab-Mohseni M; Foureau DM; Ghosh S; Walling TL; Steuerwald N; Zamor PJ; Kaplan KJ; Jacobs C; Ahrens WA; Russo MW; Clemens MG; Schrum LW; Bonkovsky HL
Liver Int; 2015 Apr; 35(4):1315-23. PubMed ID: 25302477
[TBL] [Abstract][Full Text] [Related]
60. Role of the cytosolic domain of occludin in trafficking and hepatitis C virus infection.
Lavie M; Linna L; Moustafa RI; Belouzard S; Fukasawa M; Dubuisson J
Traffic; 2019 Oct; 20(10):753-773. PubMed ID: 31328852
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
